Amylin (8-37) (human) (trifluoro<wbr/>acetate salt)

Amylin (8-37) (human) (trifluoroacetate salt)

CAT N°: 24894
Price:

€541.00 €459.85

Amylin (8-37) is a peptide fragment of amylin (Item Nos. 24274 | 24275).{41819} It inhibits osteoblast proliferation, but not bone resorption, induced by full-length human amylin and does not act as an agonist at amylin receptors. Amylin (8-37) induces formation of polymorphic fibrils containing coiled and laterally-associated sheet structures.{41820} It is cytotoxic to RINm5F islet ?-cells in vitro when used at a concentration of 25 µM, an effect that is inversely correlated with mature fibril content.{41821}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-alanyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-L-tyrosine, trifluoroacetate salt
  • Correlated keywords
    • 309244-90-4 ATQRLANFLVHSSNNFGAILSSTNVGSNTY RIN-m5F 135702-23-7
  • Product Overview:
    Amylin (8-37) is a peptide fragment of amylin (Item Nos. 24274 | 24275).{41819} It inhibits osteoblast proliferation, but not bone resorption, induced by full-length human amylin and does not act as an agonist at amylin receptors. Amylin (8-37) induces formation of polymorphic fibrils containing coiled and laterally-associated sheet structures.{41820} It is cytotoxic to RINm5F islet ?-cells in vitro when used at a concentration of 25 µM, an effect that is inversely correlated with mature fibril content.{41821}

We also advise you

Any project? Any challenge? We are in!
Contact us

Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère

78180 Montigny le Bretonneux
France

Call us
Information
My account
Follow us

Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions

Secure payment
Subscribe to our newsletter